Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: A novel mechanism of BCR-ABL1-independent disease progression

Neoplasia (United States)

Volumn 14, Issue 7, 2012, Pages 572-584

  Cerny Reiterer, Sabine ^a,b   Ghanim, Viviane ^b   Hoermann, Gregor ^b   Aichberger, Karl J ^b   Herrmann, Harald ^a   Muellauer, Leonhard ^b   Repa, Andreas ^b   Sillaber, Christian ^b   Walls, Andrew F ^c   Mayerhofer, Matthias ^b   Valent, Peter ^a,b  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; CD38 ANTIGEN; IMATINIB; INTERLEUKIN 3; MESSENGER RNA; RECOMBINANT SCATTER FACTOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; THYMIDINE; VASCULOTROPIN;

ARTICLE; BASOPHIL; CANCER GROWTH; CANCER INHIBITION; CELL DENSITY; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GROWTH REGULATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; NORTHERN BLOTTING; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84865650606     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12724     Document Type: Article

References (39)

1. Rowley JD (1973). A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290-293.
2. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Heisterkamp N, Groffen J, and Stephenson JR (1982). A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300, 765-767.
3. Heisterkamp N and Groffen J (1991). Molecular insights into the Philadelphia translocation. Hematol Pathol 5, 1-10.
4. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, et al. (1997). Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt- dependent pathway. EMBO 16, 6151-6161.
5. Deininger MW, Goldman JM, and Melo JV (2000). The molecular biology of chronic myeloid leukemia. Blood 96, 3343-3356.
6. Melo JV and Deininger MW (2004). Biology of chronic myelogenous leukaemia-signaling pathways of initiation and transformation. Hematol Oncol Clin North Am 18, 545-568.
7. Goldman JM (2009). Treatment strategies for CML. Best Pract Res Clin Haematol 22, 303-313.
8. Giles FJ, Cortes JE, Kantarjian HM, and O'Brien SM (2004). Accelerated and blastic phases of chronic myelogenous leukemia. Hematol Oncol Clin North Am 18, 753-774.
9. Melo JV and Barnes DJ (2007). Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7, 441-453.
10. Perrotti D, Jamieson C, Goldman J, and Skorski T (2010). Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 120, 2254-2264.
11. Denburg JA, Wilson WE, and Bienenstock J (1982). Basophil production in myeloproliferative disorders: increases during acute blastic transformation of chronic myeloid leukemia. Blood 60, 113-120.
12. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, and Ansari H (1998). A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90, 850-858.
13. Steegmann JL, Odriozola J, Rodriguez-Salvanés F, Giraldo P, García-Laraña J, Ferro MT, Benítez E, Pérez-Pons C, Giralt M, Escribano L, et al. (1999). Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting out- come in patients with chronic myeloid leukemia in chronic phase treated with interferon-α. Results of the CML89 trial of the Spanish Collaborative Group on interferon-α2a and CML. Haematologica 84, 978-987.
14. Deininger M (2008). Resistance and relapse with imatinib in CML: causes and consequences. J Natl Compr Canc Netw 6, 11-21.
15. Quintás-Cardama A, Kantarjian HM, and Cortes JE (2009). Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 16, 122-131.
16. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O'Brien S, Keatina M, et al. (2000). Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96, 2240-2245.
17. Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Giles FJ, Rogers A, and Albitar M (2002). Prognostic significance of cellular vascular endothelial growth fac- tor expression in chronic phase chronic myeloid leukemia. Blood 99, 2265-2267.
18. Krauth MT, Simonitsch I, Aichberger KJ, Mayerhofer M, Sperr WR, Sillaber C, Schneeweiss B, Mann G, Gadner H, and Valent P (2004). Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease. Am J Clin Pathol 121, 473-481.
19. Janowska-Wieczorek A, Majka M, Marquez-Curtis L, Wertheim JA, Turner AR, and Ratajczak MZ (2002). Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants. Leukemia 16, 1160-1166.
20. Müller A, Lange K, Gaiser T, Hofmann M, Bartels H, Feller AC, and Merz H (2002). Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukemia. Leuk Res 26, 163-168.
21. Mayerhofer M, Valent P, Sperr WR, Griffin JD, and Sillaber C (2002). BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 100, 3767-3775.
22. Sillaber C, Mayerhofer M, Aichberger KJ, Krauth MT, and Valent P (2004). Expression of angiogenic factors in chronic myeloid leukaemia: role of the bcr/abl oncogene, biochemical mechanisms, and potential clinical implications. Eur J Clin Invest 34, 2-11.
23. Hino M, Inaba M, Goto H, Nishizawa Y, Tatsumi N, Nishino T, and Morii H (1996). Hepatocyte growth factor levels in bone marrow plasma of patients with leukaemia and its gene expression in leukaemic blast cells. Br J Cancer 73, 119-123.
24. Kim JG, Sohn SK, Kim DH, Baek JH, Lee NY, Suh JS, Chae SC, Lee KS, and Lee KB (2005). Clinical implications of angiogenic factors in patients with acuteor chronic leukemia: hepatocyte growth factor levels have prognostic impact, espe- cially in patients with acute myeloid leukemia. Leuk Lymphoma 46, 885-891.
25. Zhelyazkova AG, Tonchev AB, Kolova P, Ivanova L, and Gercheva L (2008). Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia. Scand J Clin Lab Invest 68, 492-500.
26. Bühring HJ, Simmons PJ, Pudney M, Müller R, Jarrossay D, van Agthoven A, Willheim M, Brugger W, Valent P, and Kanz L (1999). The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors. Blood 94, 2343-2356.
27. McEuen AR, Buckley MG, Compton SJ, and Walls AF (1999). Development and characterization of a monoclonal antibody specific for human basophils and the identification of a unique secretory product of basophil activation. Lab Invest 79, 27-38.
28. Hoermann G, Cerny-Reiterer S, Perné A, Klauser M, Hoetzenecker K, Klein K, Müllauer L, Gröger M, Nijman SM, Klepetko W, et al. (2011). Identification of oncostatin M as a STAT5-dependent mediator of bone marrow re- modeling in KIT D816V-positive systemic mastocytosis. Am J Pathol 178, 2344-2356.
29. Agis H, Krauth MT, Böhm A, Mosberger I, Müllauer L, Simonitsch-Klupp I, Walls AF, Horny HP, and Valent P (2006). Identification of basogranulin (BB1) as a novel immunohistochemical marker of basophils in normal bone marrow and patients with myeloproliferative disorders. Am J Clin Pathol 125, 273-281.
30. Valent P, Schmidt G, Besemer J, Mayer P, Zenke G, Liehl E, Hinterberger W, Lechner K, Maurer D, and Bettelheim P (1989). Interleukin-3 is a differentiation factor for human basophils. Blood 73, 1763-1769.
31. Valent P, Besemer J, Muhm M, Majdic O, Lechner K, and Bettelheim P (1989). Interleukin 3 activates human blood basophils via high-affinity binding sites. Proc Natl Acad Sci USA 86, 5542-5546.
32. Marone G, Triggiani M, Genovese A, and De Paulis A (2005). Role of human mast cells and basophils in bronchial asthma. Adv Immunol 88, 97160.
33. de Paulis A, Prevete N, Fiorentino I, Rossi FW, Staibano S, Montuori N, Ragno P, Longobardi A, Liccardo B, Genovese A, et al. (2006). Expression and functions of the vascular endothelial growth factors and their receptors in human basophils. J Immunol 177, 7322-7331.
34. Crivellato E, Travan L, and Ribatti D (2010). Mast cells and basophils: a potential link in promoting angiogenesis during allergic inflammation. Int Arch Allergy Immunol 151, 89-97.
35. Kmiecik TE, Keller JR, Rosen E, and Vande Woude GF (1992). Hepatocyte growth factor is a synergistic factor for the growth of hematopoietic progenitor cells. Blood 80, 2454-2457.
36. Mizuno K, Higuchi O, Ihle JN, and Nakamura T (1993). Hepatocyte growth factor stimulates growth of hematopoietic progenitor cells. Biochem Biophys Res Commun 194, 178-186.
37. Galimi F, Bagnara GP, Bonsi L, Cottone E, Follenzi A, Simeone A, and Comoglio PM (1994). Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors. J Cell Biol 127, 1743-1754.
38. Nishino T, Hisha H, Nishino N, Adachi M, and Ikehara S (1995). Hepatocyte growth factor as a hematopoietic regulator. Blood 85, 3093-3100.
39. Ratajcak MZ, Marlicz W, Ratajcak J, Wasik M, Machalinski B, Carter A, and Gewirtz AM (1997). Effect of hepatocyte growth factor on early human haemato- poietic development. Br J Haematol 99, 228-236.